Overall response rate (ORR) in STEAM, a randomized, open-label, phase 2 trial of sequential and concurrent FOLFOXIRI-bevacizumab (BEV) vs FOLFOX-BEV for the first-line (1L) treatment (tx) of patients (pts) with metastatic colorectal cancer (mCRC).

Aún no traducido Aún no traducido
Este artículo no tiene resumen
Epistemonikos ID: 3a5a3e3ecc5243eb5848a5669eea30d24ea0e896
First added on: Oct 30, 2017